Clinical trial · Interventional
Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer
Toripalimab Combined With S1 and Albumin Paclitaxel as First Line in Patients With Advanced Biliary Tract Cancer: a Single-arm,One Center， Phase II Clinical Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigator's study is a single armed phrase II trial ,aiming to improve the effecacy of treatment for advanced billiary tract cancer by means of Toripalimab combining with S1 and Albumin Paclitaxel as first line in patients with advanced Biliary Tract Cancer. treatment continually until disease progression or intolerable toxicity or Patients withdrawal of consent.and target sample is 30+ patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Biliary Tract Cancer | Malignant Biliary Tract Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Toripalimab Combined With S1 and Albumin Paclitaxel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Toripalimab Combined With S1 and Albumin Paclitaxel
- interventionNames
- Drug: Toripalimab Combined With S1 and Albumin Paclitaxel
Primary outcomes (1)
- measure
- objective response rate
- timeFrame
- 1 year
- description
- ORR
Secondary outcomes (3)
- measure
- progression free survival
- timeFrame
- 1 year
- description
- PFS
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old 2. Patients with gallbladder and cholangiocarcinoma diagnosed by histology or cytology 3. Liver function Child-Pugh grade A (5-6 points) or better grade B (≤ 7 points) 4. ECOG score 0 or 1 point 5. At least one measurable lesion 6. no previous treatment Exclusion Criteria: 1. organs failure ,including liver ,heart ,kidney 2. Have received a liver transplant in the past 3. Active brain metastasis or spinal cord compression 4. ECOG score 3 or 4 point 5. Symptomatic peripheral neuropathy (CTCAE ≥ 2)
References
Publications (0)
Data not yet available